Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients.
The aim of this study was to compare, using gamma scintigraphy, the lung deposition of a novel mucoactive agent, Nacystelyn (NAL), administered as a dry powder inhaler (DPI) in six healthy volunteers, six adult patients with cystic fibrosis (CF), and six children and adolescents patients with CF. The correlation between in vitro and in vivo results was also tested. It was first demonstrated that the method of labeling of NAL with 99mTc was reliable as tested by three in vitro methods (multistage liquid impinger, multistage cascade impactor, and 2-stage glass impinger). The deposition of unlabeled NAL, labeled NAL, and the radiolabel was similar in all stages of each device. Furthermore, the fine particle fraction (FPF) was the same on all apparatuses. The mean lung deposition obtained in volunteers was 27.5 +/- 13.5%. The results are approximately three times higher than the results obtained previously in healthy volunteers with NAL metered-dose inhalers (MDIs). As expected, the lung deposition observed in patients with CF was lower, e.g., 23.5 +/- 7.0% for adults and 16.5 +/- 5.9% for children and adolescents. A significant correlation was found between lung deposition and both the patient weight (p < 0.02) and height (p < 0.04). Surprisingly, the peripheral:central (P:C) ratio was similar for the three populations, indicating that the presence of mucus in moderately ill patients with CF does not modify the lung distribution of NAL. The FPF measured in vitro was similar to that obtained in volunteers but higher than that found in both patient populations. The DPI formulation of NAL developed will probably improve patient compliance and comfort in future clinical trials and postmarketing use of the drug.
Vanderbist
F
F
Laboratoires SMB, rue de la Pastorale 26-28, 1080 Brussels, Belgium.
Wery
B
B
Baran
D
D
Van Gansbeke
B
B
Schoutens
A
A
Moës
A J
AJ
D000042:Absorption; D000111:Acetylcysteine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D002648:Child; D003550:Cystic Fibrosis / Q000000981:diagnostic imaging / Q000378:metabolism*; D005100:Expectorants / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005260:Female; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging / Q000378:metabolism*; D008239:Lysine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D008297:Male; D011208:Powders; D011877:Radionuclide Imaging; D013667:Technetium; D014018:Tissue Distribution
D005100:Expectorants; C086501:N-acetylcysteine lysinate; D011208:Powders; D013667:Technetium; D008239:Lysine; D000111:Acetylcysteine